FDA Clears Lightning CAVT for Deep Vein Thrombosis

Lightning CAVTWhat to know

30-second read

For Vascular Surgery · Radiology

Who

Adults with symptomatic acute iliofemoral DVT who could be candidates for catheter-based thrombus removal — not a replacement for anticoagulation in routine DVT.

What it does

A single-session aspiration thrombectomy device, now cleared to remove clot directly from the vein in DVT rather than waiting on anticoagulation alone.

Evidence

BOLT-DVT (229 patients, single-arm): 98% complete/near-complete thrombus removal, 18-minute median device time, 3.1% major adverse events at 48 hours; not yet peer-reviewed.

What’s different

A dedicated 229-patient IDE trial backs this clearance; older DVT-labeled devices relied on predicate equivalence, not a pivotal trial of their own.

Key consideration

FDA clearance isn’t a guideline endorsement — CHEST still weakly favors anticoagulation alone for routine DVT; check whether this patient fits the trial’s own criteria.

Availability

Commercially available now on Penumbra’s existing Indigo/Lightning platform, already stocked for PE and arterial thrombectomy; the 510(k) number is not yet publicly indexed.

Practice impactConsider in selected iliofemoral DVT

A genuine new option for symptomatic iliofemoral DVT in patients who fit the trial's criteria — not a reason to abandon anticoagulation alone as the guideline-preferred default for ordinary DVT.

Read the full physician analysis

Full analysis · 11 min readPenumbra’s FDA clearance announcement · BOLT-DVT (NCT05003843) · CHEST 2021 guideline · ATTRACT (NEJM 2017)

FDA cleared Penumbra’s Lightning computer-assisted vacuum thrombectomy (CAVT) system for deep vein thrombosis on 20 October 2026, giving vascular surgeons and interventional radiologists a device whose DVT indication is now backed by a dedicated, prospective pivotal trial rather than the predicate-equivalence filings that have carried older devices into the same disease for a decade. Penumbra’s own announcement calls it the first cleared DVT indication among mechanical thrombectomy devices — a claim that does not survive contact with the regulatory record.

A claim the press releases didn't challenge

Every trade outlet that covered this clearance repeated Penumbra’s framing: the first FDA-cleared DVT indication among mechanical thrombectomy devices. It is worth stopping on that sentence before anything else, because it is not accurate as stated. Boston Scientific’s AngioJet ZelanteDVT catheter received FDA clearance and a CE mark in November 2015 specifically to break apart and remove thrombus, including DVT, from iliofemoral and lower-extremity veins. Inari Medical’s ClotTriever has carried “peripheral vasculature including deep vein thrombosis (DVT)” language in its FDA clearance since roughly 2020. Neither device has disappeared from practice; both are commonly used for DVT today.

The more defensible version of Penumbra’s claim is narrower: Lightning CAVT’s DVT indication is the first in this category to rest on a dedicated, prospective Investigational Device Exemption trial built around DVT specifically, rather than on 510(k) predicate-equivalence to a device already cleared for something else. AngioJet and ClotTriever earned their DVT-inclusive language through the standard substantial-equivalence pathway; BOLT-DVT was a company-run pivotal study enrolling 229 patients across 39 sites for this indication alone. That is a real and clinically relevant distinction — prospective trial data is not nothing — but it is a different and smaller claim than “first cleared,” and Regulatory News asked Penumbra to clarify the wording before publication; the company had not responded as of this writing.

What BOLT-DVT actually measured

BOLT-DVT was a prospective, multicenter IDE trial that used CAVT as first-line treatment for acute iliofemoral DVT in 229 adults (mean age 58.1, 62% female) at 39 U.S. sites. There was no anticoagulation-alone comparison arm — every enrolled patient received the device. Investigators, led by vascular surgeon Patrick Muck, MD, of TriHealth in Cincinnati, presented primary results as a late-breaking trial at the combined VEINS and VIVA 2026 meeting in Las Vegas in early October. The study has not yet appeared in a peer-reviewed journal, so the figures below come from conference and company reporting, not a published manuscript.

BOLT-DVT, as reported at VEINS and VIVA 2026

98%of evaluable patients (198 of 202) had complete or near-complete (≥75%) thrombus removal; median reduction was 100%

18 minmedian device time to clear the clot in a single session

3.1%major adverse event rate at 48 hours (7 of 229 patients) — no device-related deaths

229patients at 39 U.S. sites; single-arm, no anticoagulation-alone comparator

From BOLT-DVT (NCT05003843) as presented at VEINS and VIVA 2026 and in Penumbra's 20 October 2026 announcement; not yet published in a peer-reviewed journal.

Penumbra’s own reporting breaks the 3.1% 48-hour major adverse event rate down as roughly 1.3% major bleeding, 0.9% symptomatic pulmonary embolism and 1.3% rethrombosis — the categories appear to overlap slightly across the company’s own figures, so treat the breakdown as approximate rather than independently adjudicated. At 30 days, the company reports a 3.9% re-thrombosis rate, vessel patency of 88.8% to 96.3% depending on segment, and 84.3% of patients free of post-thrombotic syndrome symptoms. Those 30-day figures trace to Penumbra’s own release rather than to independent trade coverage; they are plausible but unverified outside the sponsor.

Lightning CAVT against the devices already used for DVT

	Lightning CAVT	AngioJet ZelanteDVT	ClotTriever
DVT clearance basis	Dedicated IDE trial (BOLT-DVT), Oct 2026	510(k) predicate equivalence, Nov 2015	510(k) predicate equivalence, DVT language added ~2020
Mechanism	Computer-assisted vacuum aspiration	Rheolytic (high-pressure saline jet) maceration and aspiration	Mechanical coring and aspiration
DVT-specific trial data	BOLT-DVT, 229 patients, single-arm, not yet published	No dedicated pivotal DVT trial identified	CLOUT registry, real-world, single-arm, not a company-sponsored pivotal trial
Notable safety signal	3.1% 48-hour MAE in BOLT-DVT	Boxed warning for pulmonary embolism use (not DVT); hemolysis risk from the rheolytic mechanism	No boxed warning identified

AngioJet and ClotTriever particulars from Boston Scientific's and Inari's own clearance and safety materials as reported in trade and regulatory coverage. Prescribe and select devices from each manufacturer's current labeling, not this table.

Why anticoagulation alone is still the guideline default

The clinical trial that looms over any mechanical-thrombectomy claim in DVT is ATTRACT, a 692-patient randomized trial (Vedantham et al., NEJM 2017) that compared pharmacomechanical catheter-directed thrombolysis plus anticoagulation against anticoagulation alone for acute proximal DVT. Its primary endpoint — post-thrombotic syndrome (PTS) at 24 months — was negative: 46.7% in the intervention arm versus 48.2% with anticoagulation alone, not statistically significant, and the same held in the iliofemoral subgroup (49% versus 51%). Major bleeding was higher with intervention (1.7% versus 0.3%). ATTRACT did find a secondary signal worth remembering: moderate-to-severe PTS specifically was lower with intervention (18% versus 24%), which investigators called hypothesis-generating rather than practice-changing.

That negative primary endpoint is why CHEST’s 2021 antithrombotic therapy guideline still recommends anticoagulant therapy alone over interventional therapy — thrombolytic, mechanical, or pharmacomechanical — for acute DVT of the leg, a weak recommendation based on moderate-certainty evidence. The guideline carves out an exception for limb-threatening presentations such as phlegmasia cerulea dolens, where faster clot resolution may outweigh the added bleeding risk, but otherwise the default has not moved. An older, narrower guideline — the 2012 SVS/American Venous Forum consensus — gives a weak (Grade 2C) recommendation in favor of early thrombus removal in a specific subset: first-episode iliofemoral DVT, symptom onset under 14 days, low bleeding risk, ambulatory patients with reasonable life expectancy. BOLT-DVT’s own enrollment criteria track that same subset closely. A device clearance does not update a guideline; CHEST would need its own review cycle to weigh BOLT-DVT once it is published, and ATTRACT’s negative primary endpoint is the evidence base a new single-arm device trial has not yet answered.

Who actually fits the trial's population

BOLT-DVT enrolled patients with acute iliofemoral DVT — clot in the common femoral or iliac veins, not isolated below-knee disease — which is the same population guideline-writers have long treated as the plausible candidate for early intervention. Across the SVS/AVF consensus and the device literature more broadly, the recurring selection criteria are symptom onset within about 14 days (some specialists prefer a tighter 7-day window, based on post hoc ATTRACT analyses showing intervention worked better closer to clot formation), low bleeding risk, ambulatory functional status, and a reasonable life expectancy. NICE guidance on percutaneous mechanical thrombectomy recommends the decision go through multidisciplinary assessment — vascular surgery, interventional radiology and hematology together — rather than a single proceduralist’s call.

What the trial does not tell a physician is where the line sits for more distal or more chronic clot, since BOLT-DVT restricted itself to acute iliofemoral disease. A patient with isolated calf-vein DVT, or clot present for weeks rather than days, is outside what this clearance’s own evidence covers, whatever the device’s broader labeling allows.

The codes, the setting, and who pays

Mechanical thrombectomy for venous thrombosis already has an established CPT structure: 37187 covers the initial percutaneous mechanical thrombectomy procedure, with 37188 for a repeat treatment on a subsequent day during a course of thrombolytic infusion. That code set predates this clearance and does not change with it — Lightning CAVT bills under the same codes used for the device’s existing PE and arterial indications. A separate code, HCPCS C7564, covering venous mechanical thrombectomy performed with intravascular ultrasound guidance, became eligible for ambulatory surgical center performance effective 1 January 2025 under CMS rules, according to a code-lookup reference; practices should confirm current status directly against the CMS physician fee schedule and OPPS/ASC final rule before relying on it, since this desk could not independently verify it against a primary CMS document this run. The direction, if it holds, matters for site-of-care economics: DVT thrombectomy has largely been a hospital-based procedure, and ASC eligibility would shift where it can be performed and billed.

What changes for vascular surgeons and interventional radiologists

• Patient selection stays the gatekeeper. This clearance adds a device option within the same narrow, guideline-recognized population — acute iliofemoral DVT, short symptom duration, low bleeding risk, ambulatory — not a broader indication for routine DVT.
• Anticoagulation alone remains the guideline-preferred default for ordinary acute DVT per CHEST 2021. Reach for mechanical thrombectomy where the clinical picture already matched the SVS/AVF early-intervention criteria, not as a new first-line standard.
• Competitive context matters at the device-selection level. AngioJet ZelanteDVT and ClotTriever already compete here; BOLT-DVT gives Lightning CAVT its own dedicated trial data set, which a value-analysis committee or credentialing body may now ask for explicitly.
• Site-of-care and billing follow the existing venous-thrombectomy codes (CPT 37187/37188); confirm any ASC-eligibility change locally before shifting where a case is scheduled.
• The evidence is not yet peer-reviewed. BOLT-DVT's figures come from conference presentation and company reporting; treat the 30-day patency and PTS-free figures, sourced only to Penumbra, with appropriate caution until independently published.

From a stroke-thrombectomy platform to a DVT clearance

1. 2004

   Penumbra founded

   Founded in Alameda, California, by Arani Bose, MD, and Adam Elsesser, initially targeting ischemic stroke thrombectomy.

2. Nov 2015

   AngioJet ZelanteDVT cleared

   Boston Scientific's rheolytic thrombectomy catheter becomes the first widely used device cleared specifically for iliofemoral and lower-extremity DVT.

3. ~2020

   ClotTriever's DVT language

   Inari Medical's ClotTriever 510(k) clearance adds DVT-inclusive peripheral-vasculature labeling.

4. 2024

   Lightning Flash 2.0 cleared

   The CAVT platform's prior FDA clearance, for venous thrombus removal and pulmonary embolism — not yet DVT-specific.

5. 20 Oct 2026

   Lightning CAVT cleared for DVT

   FDA clearance for the deep vein thrombosis indication, based on the BOLT-DVT IDE trial.

6. Ahead

   Peer review and guideline review still pending

   BOLT-DVT has not yet been published in a peer-reviewed journal; CHEST's next antithrombotic-guideline review cycle has not weighed it.

Frequently asked questions

Is Lightning CAVT really the first device cleared for DVT?

Not in the way the headline implies. Boston Scientific's AngioJet ZelanteDVT catheter has carried an FDA clearance naming iliofemoral and lower-extremity DVT specifically since November 2015, and Inari's ClotTriever has carried DVT-inclusive 510(k) labeling since around 2020. What is new is that Lightning CAVT's DVT indication rests on a dedicated, prospective pivotal trial (BOLT-DVT) rather than a standard predicate-equivalence 510(k) filing — a real distinction, but a narrower one than "first cleared."

Does this clearance change DVT treatment guidelines?

No. CHEST's 2021 antithrombotic guideline still gives a weak recommendation favoring anticoagulation alone over any interventional therapy for ordinary acute DVT, based on ATTRACT's negative primary endpoint. An FDA clearance is not a guideline update; CHEST would need its own review cycle to weigh BOLT-DVT, which is not yet peer-reviewed.

Who was actually studied in BOLT-DVT?

229 adults with acute iliofemoral DVT at 39 U.S. sites, mean age 58, 62% female, treated with CAVT as first-line therapy in a single-arm design — there was no anticoagulation-alone comparison arm. Investigators reported 98% complete or near-complete thrombus removal, an 18-minute median device time, and a 3.1% major adverse event rate at 48 hours.